Omalizumab
| |
| Klinički podaci | |
|---|---|
| AHFS/Drugs.com | Monografija |
| Identifikatori | |
| CAS broj | 242138-07-4 |
| ATC kod | R03DX05 |
| DrugBank | DB00043 |
| ChEMBL[1] | CHEMBL1201589 
|
| Hemijski podaci | |
| Formula | C6450H9916N1714O2023S38 |
| Mol. masa | 145058,2 g/mol |
| Fizički podaci | |
| Tačka topljenja | 61 °C (142 °F) |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 26 dana |
| Izlučivanje | Renalno, bilijarno |
| Farmakoinformacioni podaci | |
| Trudnoća | ? |
| Pravni status | |
| Način primene | Subkutano |
Omalizumab (Xolair) je humanizovano antitelo koje se koristi za redukovanje senzitivnosti na udahnute ili progutane alergene, posebno za kontrolu umerene do jake alergijske astme, koja nije responsivna na visoke doze kortikosteroida. Omalizumab je rekombinantno DNK-izvedeno IgG1k monoklonalno antitelo, koje se selektivno vezuje za ljudski imunoglobulin E (IgE). Xolair se proizvodi pomoću CHO ćelija.[2][3][4]
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, Thompson RG, Durham SR, Schwartz LB, Balkwill FR, Gould HJ: Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol. 2003 Apr;33(4):1030-40. PMID 12672069
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
